Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 2211: STAT1 and STAT3 cooperatively control cancer stem cell (CSC) fate and IFNγ-dependent CSC maintenance.

View through CrossRef
Abstract Background: Cancer stem cells (CSCs) are a rare tumor cell subset with self-renewal and differentiation capacity that drives tumor initiation, heterogeneity, metastasis, and therapy resistance. Interferon-γ (IFNγ) has been implicated in regulating CSC fate, but its effects are highly context dependent. How the intrinsic balance between opposing IFNγ pathway effectors such as STAT1 and STAT3 shapes CSC properties remains poorly understood. Methods: Breast (4T1, PY230) and sarcoma (F244, F236, H74) cell lines were exposed to high acute or persistent IFNγ stimulation. STAT1/STAT3 were deleted via CRISPR-Cas9. Retroviral transfection was used to restore STAT1 in STAT1-deficient H74 sarcoma cells. CSC induction was monitored using molecular and sphere formation assays for in vitro and in vivo experiments. Bioinformatic analyses include single-cell and bulk-RNA sequencing from public databases of human breast cancer. Results: In this study, we found that cancer cell lines with higher expression of stem-cell-associated markers at baseline tend to have a lower STAT1/ STAT3 ratio and/or constitutive STAT3 activation. Exposure to acute high dose of IFNγ or persistent exposure to IFNγ led a progressive increase of CSC-associated genes (e.g. Zeb1, Bst2, Tert). STAT1 depletion favored CSC induction, while STAT3 loss led to increased cell death both with or without IFNγ stimulation. Interestingly, combined STAT1/STAT3 depletion markedly increased sphere size independently of IFNγ treatment, indicating that those two transcription factors may cooperate to restrain CSC proliferation. In vivo, STAT1-deficient H74 sarcoma cell line exhibited accelerated tumor progression and CSC induction in an IFNγ-dependent manner. By contrast, restoration of STAT1 completely abrogated H74 tumor growth in immunocompetent but not immunodeficient mice, confirming that STAT1 limits CSC induction by sensitizing tumor cells to immune-mediated cytotoxicity. Finally, single-cell RNAseq of human breast cancer cells revealed an inverse correlation between STAT1 and STAT3 expressions. STAT1-negative tumor cells with high IFNγ score were enriched in EMT- and apoptosis-related programs. Consistently, IFNγhi/STAT3hi breast tumors exhibited a stronger EMT signature and were associated with poorer clinical outcomes compared with IFNγhi/STAT3lo tumors. Conclusions: Modulating the STAT1/STAT3 balance can suppress CSC expansion and preserve tumor cell vulnerability to immune-mediated killing. STAT1-sufficient tumors respond to IFNγ typically by increasing immunogenicity and limiting CSC potential, whereas STAT1-deficient tumors respond to IFNγ by increasing CSC properties. These results suggest that STAT1 serves as a toggle for anti- and pro-tumor effects of IFNγ. Citation Format: Sophia Hidalgo, Anushka Poola, Yipeng Zhang, Rachel Zhou, Kourosh Kouhmareh, Jack D. Bui, Magalie Dosset. STAT1 and STAT3 cooperatively control cancer stem cell (CSC) fate and IFNγ-dependent CSC maintenance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2211.
Title: Abstract 2211: STAT1 and STAT3 cooperatively control cancer stem cell (CSC) fate and IFNγ-dependent CSC maintenance.
Description:
Abstract Background: Cancer stem cells (CSCs) are a rare tumor cell subset with self-renewal and differentiation capacity that drives tumor initiation, heterogeneity, metastasis, and therapy resistance.
Interferon-γ (IFNγ) has been implicated in regulating CSC fate, but its effects are highly context dependent.
How the intrinsic balance between opposing IFNγ pathway effectors such as STAT1 and STAT3 shapes CSC properties remains poorly understood.
Methods: Breast (4T1, PY230) and sarcoma (F244, F236, H74) cell lines were exposed to high acute or persistent IFNγ stimulation.
STAT1/STAT3 were deleted via CRISPR-Cas9.
Retroviral transfection was used to restore STAT1 in STAT1-deficient H74 sarcoma cells.
CSC induction was monitored using molecular and sphere formation assays for in vitro and in vivo experiments.
Bioinformatic analyses include single-cell and bulk-RNA sequencing from public databases of human breast cancer.
Results: In this study, we found that cancer cell lines with higher expression of stem-cell-associated markers at baseline tend to have a lower STAT1/ STAT3 ratio and/or constitutive STAT3 activation.
Exposure to acute high dose of IFNγ or persistent exposure to IFNγ led a progressive increase of CSC-associated genes (e.
g.
Zeb1, Bst2, Tert).
STAT1 depletion favored CSC induction, while STAT3 loss led to increased cell death both with or without IFNγ stimulation.
Interestingly, combined STAT1/STAT3 depletion markedly increased sphere size independently of IFNγ treatment, indicating that those two transcription factors may cooperate to restrain CSC proliferation.
In vivo, STAT1-deficient H74 sarcoma cell line exhibited accelerated tumor progression and CSC induction in an IFNγ-dependent manner.
By contrast, restoration of STAT1 completely abrogated H74 tumor growth in immunocompetent but not immunodeficient mice, confirming that STAT1 limits CSC induction by sensitizing tumor cells to immune-mediated cytotoxicity.
Finally, single-cell RNAseq of human breast cancer cells revealed an inverse correlation between STAT1 and STAT3 expressions.
STAT1-negative tumor cells with high IFNγ score were enriched in EMT- and apoptosis-related programs.
Consistently, IFNγhi/STAT3hi breast tumors exhibited a stronger EMT signature and were associated with poorer clinical outcomes compared with IFNγhi/STAT3lo tumors.
Conclusions: Modulating the STAT1/STAT3 balance can suppress CSC expansion and preserve tumor cell vulnerability to immune-mediated killing.
STAT1-sufficient tumors respond to IFNγ typically by increasing immunogenicity and limiting CSC potential, whereas STAT1-deficient tumors respond to IFNγ by increasing CSC properties.
These results suggest that STAT1 serves as a toggle for anti- and pro-tumor effects of IFNγ.
Citation Format: Sophia Hidalgo, Anushka Poola, Yipeng Zhang, Rachel Zhou, Kourosh Kouhmareh, Jack D.
Bui, Magalie Dosset.
STAT1 and STAT3 cooperatively control cancer stem cell (CSC) fate and IFNγ-dependent CSC maintenance [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2211.

Related Results

Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract Background The STAT3 pathway may drive prostate cancer (PCa) progression to metastatic castration-resistant prostate cancer (mCRPC). STAT3 may serve as a go...
Abstract 1600: Dose-dependent effects of interferon-gamma treatment on pancreatic ductal adenocarcinoma cell states
Abstract 1600: Dose-dependent effects of interferon-gamma treatment on pancreatic ductal adenocarcinoma cell states
Abstract Interferon-gamma (IFNγ) is a canonical proinflammatory cytokine that has well-studied antitumor functions such as the upregulation of MHC Class I (MHC-I), i...
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract Approximately 13% of women are diagnosed with invasive breast cancer. Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor t...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer
A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer
Abstract Background Colorectal cancer (CRC) is a worldwide cancer with rising annual incidence. New medications for patients with CRC are still need...
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Abstract Abstract 2849 Poster Board II-825 Histone deacetylase inhibitors (HDACi) are emerging as a potential therapy for Multiple Myel...
Abstract 1624: Stat1 promotes lesion growth and tumor immunity of tuberin-deficient cells in lymphangioleiomyomatosis
Abstract 1624: Stat1 promotes lesion growth and tumor immunity of tuberin-deficient cells in lymphangioleiomyomatosis
Abstract Lymphangioleiomyomatosis (LAM) is a cystic lung disease that primarily affects women, with an estimated global prevalence of 19 per million women. LAM is ca...
O18 Molecular crosstalk between PLCγ1 and STAT3 in cutaneous T-cell lymphoma
O18 Molecular crosstalk between PLCγ1 and STAT3 in cutaneous T-cell lymphoma
Abstract Cutaneous T-cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes that is difficult to diagnose and treat due to a high degree of clin...

Back to Top